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Abstract
Background: Clostridium difficile infection (CDI) and Klebsiella pneumoniae carbapenemase producing-Klebsiella
pneumoniae (KPC-Kp) bloodstream infection (BSI) are emerging health-care associated (HCA) diseases of public
health concern, in terms of morbidity, mortality, and insufficient response to antibiotic therapy. Both agents can be
acquired in the hospital but clinical disease can develop in a community setting, after discharge. We report here
a putative link between the above-mentioned healthcare associated infections that appeared as a dramatic
community onset disease with a fulminant fatal outcome.
Case presentation: We describe the case of a 63 year old man affected by severe CDI. Even though the patient
underwent 72 hours of standard CDI antibiotic treatment, the clinical course was complicated by toxic
megacolon and KPC-Kp BSI. The patient died 24 hours after total colectomy.
Conclusion: The impact of HCA-BSIs in complicating CDI is still unknown. Intestinal inflammatory injury and disruption
of intestinal flora by standard antibiotic treatment could be responsible for promoting difficult-to-treat infections in CDI.
By preserving intestinal flora, Fidaxomicin could have a crucial role in preventing BSIs complicating severe CDI.
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Background
The impact of health-care associated (HCA) bloodstream
infection (BSI) in complicating Clostridium difficile infec-
tion (CDI) is still unknown. We describe for the first time
a case of community onset healthcare-associated severe
CDI complicated by Klebsiella pneumoniae Carbapene-
mase producing Klebsiella pneumoniae (KPC-Kp) BSI.
CDI and KPC-Kp BSI are recently emerging as two of the
more concerning HCA diseases in terms of morbidity,
mortality, and inefficient response to antibiotic therapy. A
relation between the above-mentioned infections have
never been reported until now.
Case presentation
We report the case of a 63 year old man, who was ad-
mitted on the 6th of February 2014 to the Intensive Care
Unit (ICU) of a 1300-bed teaching Institution in Rome
because of septic shock syndrome. His past medical his-
tory was remarkable for high blood pressure, multi-infarct
dementia, Parkinson’s disease and depressive disorder.
The patient had been hospitalized on the 15th of January
2014 in a peripheral center for a febrile syndrome due to a
urinary tract infection caused by Escherichia coli. During
his hospital stay, he underwent a ten-day course of anti-
microbial therapy with intravenous ciprofloxacin and was
discharged on the 28th of January on treatment with oral
Cefditoren pivoxil. On the 3rd of February, the patient
was readmitted to the same hospital because of confusion,
fever and diarrhea. Clostridium difficile infection (CDI)
test was performed (Alere™ C. DIFF QUICK CHECK
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COMPLETE for simultaneous detection of both glutamate
dehydrogenase antigen and toxin A and B). Oral vanco-
mycin 500 mg q6h, intravenous metronidazole 500 mg
q6h and intravenous Piperacillin/tazobactam 4.5 g q8h
were immediately started. After 72 hours of persistent de-
terioration despite standard antibiotic therapy administra-
tion, the patient was transferred to the ICU of our
hospital. At the admission the patient was unconscious
(Glasgow Coma Scale of 3), presenting with ileus and sep-
tic shock syndrome. Oro-tracheal intubation and fluid re-
suscitation were performed followed by intravenous
norepinephrine. Tigecycline was empirically added to the
combination antimicrobial therapy. Three blood cultures
were drawn and blood test showed 24000 white blood
cells/μl, creatinine 3.6 mg/dl, albumin 2.2 g/dl, lactate
4 mmol/l. Computed tomography scans demonstrated
findings compatible with toxic megacolon. A total colec-
tomy was performed but the patient died 24 h after the
surgical intervention. All blood cultures drawn at the time
of admission to the ICU were positive for a carbapenem-
resistant strain of Klebsiella pneumoniae (Vitek 2 system,
AST-N089 card bioMérieux, Marcy l’Etoile, France, MICs:
Amikacin ≥ 64 mg/l, Amoxicillin/Clavulanic acid ≥ 32 mg/l,
Cefepime ≥ 64 mg/l, Cefotaxime ≥ 64 mg/l, Ceftazidime ≥
64 mg/l, Ciprofloxacin ≥ 4 mg/l, Colistin ≥ 16 mg/l, Ertape-
nem ≥ 8 mg/l, Fosfomycin ≥ 256 mg/l, Gentamicin 4 mg/l,
Imipenem ≥ 16 mg/l, Meropenem ≥ 16 mg/l, Piperacillin/
Tazobactam ≥ 128 mg/l, Tigecycline 4 mg/l, Trimethoprim/
Sulfamethoxazole ≥ 320 mg/l). Production of KPC enzyme
was documented by using a phenotypic test based on the
inhibitory activity of boronic acid compounds as reported
by Pournaras et al. [1], and carbapenemase producing-
Klebsiella pneumoniae (KPC-Kp) was identified. In
addition, one blood culture was positive for vancomycin-
susceptible Enterococcus faecium. Histologic examination
of the colon confirmed diagnosis of pseudomembraneous
colitis.
Discussion and conclusion
We believe that this case report is of great interest because
our patient contemporarily developed two community-
onset healthcare associated infections with a rapidly fatal
outcome. Carbapenem-resistant Enterobacteriaceae (CRE)
are an emerging issue of great public health concern. In
our country, the problem is almost completely represented
by carbapenem-resistant K. pneumoniae. Even though data
related to incidence are missing, percentage of invasive K.
pneumoniae isolates with resistance to carbapenems report-
edly ranges between 25% and 50% in Italy [2]. Recently,
cases of healthcare-associated carbapenem resistant K.
pneumoniae BSIs have been reported in Northern Italy [3].
The phenomenon is also well known in Rome [4] and par-
allels to an epidemiological shift of CDI occurring in our re-
gion and consisting of increased disease incidence and
mortality rates [5,6], that are probably due to the spread of
the epidemic strain ribotype 027 CD [6-8]. In the present
case, because the initial diagnosis was made in a peripheral
center, ribotyping test was not performed. We describe, for
the first time, a fatal case of severe CDI complicated by
KPC-Kp BSI. This led us to question about the role of se-
vere CDI on predisposing to HCA-BSIs, and vice-versa, on
the role of HCA-BSIs in determining the prognosis of se-
vere CD colitis. To our knowledge this issue has never been
thoroughly evaluated in the literature until now.
We already disserted on the putative correlation be-
tween CDI and Candida spp. BSI [9]. Analogous mecha-
nisms could be advocated to explain the link between CDI
and KPC-Kp BSI. Recently, Perez et al. demonstrated in a
mouse model the impact of the administration of antibi-
otics effective against intestinal flora on promoting the
persistence of KPC-Kp colonization of the gastrointestinal
tract [10]. Edlund et al., evaluating the ecological distur-
bances of oral vancomycin following cephalosporin
administration in 20 healthy volunteers, showed intes-
tinal Klebsiella spp. overgrowth within 3 days of vanco-
mycin treatment [11]. In the present case, KPC-Kp
colonization was acquired in a non-ICU setting, an
emerging phenomenon already described in our country
[12]. Oral vancomycin administration, highly active
against the intestinal flora [13], could have been respon-
sible for persistence and overgrowth of KPC-Kp in the
gastrointestinal tract. Gut inflammatory injury caused
by severe CDI could be considered the “second hit”
allowing bacterial translocation and BSI. The role of se-
vere intestinal inflammation predisposing to bacterial
mucosal penetration and blood invasion has been
already showed in murine and human models [14,15].
Moreover, K. pneumoniae has been demonstrated to be
one of the most efficient microorganisms in translocat-
ing to extraintestinal sites, presenting a very low
bacteremia clearance in the liver and spleen [16].
Colonic inflammation induced by severe CDI and stand-
ard CD antibiotic treatment could promote difficult-to-
treat infections/colonizations (i.e. KPC-Kp BSI, Candida
spp. BSI [6], or vancomycin resistant-enterococci intestinal
colonization [17]. Fidaxomicin, a newly licensed macro-
cyclic antibiotic recently approved to treat CDI, is charac-
terized by a narrow spectrum of activity almost limited to
CD and consequent preservation of intestinal flora com-
pared to vancomycin [13]. Preservation of intestinal flora
could represent a useful therapeutic option not only in re-
ducing CDI recurrence rate [9], but also in preventing
BSIs secondary to severe CDI.
In conclusion, clinical impact of BSIs on complicating
CDI has not been systematically evaluated until now.
Fidaxomicin could represent a useful therapeutic option
in preventing difficult-to-treat BSIs secondary to severe
CDI. Studies are necessary to validate this hypothesis.
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